Company intelligence / Profile preview

X-Biotix Therapeutics

Waltham, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

X-Biotix Therapeutics is an early preclinical-stage biotech spun out of X-Chem in 2016 to discover and develop novel small molecule antibiotic scaffolds targeting multi-drug resistant Gram-negative pathogens, using DNA-encoded library technology to generate leads against multiple essential bacterial targets; no clinical-stage assets have been publicly disclosed to date.[5][7][8][9]

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

X-Chem (spin-out and technology collaboration using DEX DNA-encoded library platform)[7][9]Harvard University (technology license for antibiotic discovery)[4][7]Collaboration with investigators in the Department of Microbiology and Immunobiology at Harvard Medical School[7]

Beyond the preview

Go deeper on X-Biotix Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on X-Biotix Therapeutics.

Explore the full profile